Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia

NCTNCT00716170 (opens ClinicalTrials.gov in a new tab)Other id1301831410
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
10 participants (actual)
Sponsor
Herlev Hospital · Other
Design
Not stated
Countries
1 country

Denmark

Start
Jul 2008
Primary completion
Jul 2009
Completion
Jul 2009
First posted
16 Jul 2008 (estimated)
Last update posted
28 Nov 2013 (estimated)
Conditions
Type 2 Diabetes Mellitus

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200820092010
  1. Ph –

    GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia

    NCT00716170

    Jul 2008 to Jul 2009

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

In order to investigate the mechanisms underlying the hyperglucagonemia characterizing patients with type 2 diabetes mellitus (T2DM) we wish to test the following hypothesis: Do pancreatic alpha-cells exhibit inappropriate glucagon responses to substances released from the small intestine (GIP, GLP-2 and GLP-2) in patients with T2DM?

Interventions

  • Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)Biological

Arms1

  • Other

    A:

    Patients with type 2 diabetes mellitus

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Plasma glucagon responses

    Time frame · 3 hours

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

PubMed tag: none · 2000

5 results

Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.

Shah et al. 2000The Journal of clinical endocrinology and metabolismcited by 305

PMID 11095432DOI 10.1210/jcem.85.11.6993PUB-11095432

Full text at the publisher5 results
Publisher pageSee results (5)

Eligibility

Who could join, as posted.

Sex
All
Age
from 35 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Caucasians with diet and/or tablet treated T2DM of at least 3 months duration (diagnosed according to the criterias of the World Health Organization (WHO)) * Normal Hemoglobin * Prior Informed Consent Exclusion Criteria: * Liver disease (ALAT/ASAT \> 2 x upper normal value) * Diabetic nephropathy (se-creatinin \> 130 um and/or albuminuria * Treatment with drugs that cannot be discontinued for 12 hours

PepBank is a research reference. Talk to a doctor before you use any peptide.